Mode
Text Size
Log in / Sign up

ABO-Incompatible Liver Transplant Outcomes Comparable in ChildrenIncompatible blood types do not lower survival in pediatric liver transplants

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
ABO-incompatible pediatric liver transplants yield similar survival and complications, but antibody-mediated rejection risk is significantly higher.

A meta-analysis evaluated outcomes of ABO-incompatible (ABO-i) versus ABO-compatible (ABO-c) liver transplantation in pediatric recipients (≤18 years). Pooled data from observational studies showed no significant differences in 1-, 3-, and 5-year patient survival (risk ratios 0.97, 0.98, and 0.97, respectively) or graft survival. Vascular complications, biliary complications, acute rejection, CMV/EBV infections, and post-transplant lymphoproliferative disease also occurred at similar rates between groups.

However, antibody-mediated rejection (AMR) was markedly more frequent in ABO-i recipients, with a risk ratio of 20.04 (95% CI 3.25-123.56, p=0.001). This finding, based on only four studies, warrants cautious interpretation. The overall certainty of evidence was very low due to the observational design and risk of bias in included studies.

Despite the AMR risk, the comparable survival and complication profiles suggest that ABO-i liver transplantation can be a viable option in pediatric patients when compatible organs are scarce. Clinicians should weigh the increased AMR risk against the potential benefits of timely transplantation. Further high-quality studies are needed to confirm these findings and refine management strategies.

How this fits prior evidence

This meta-analysis addresses a gap in the clinical management of pediatric liver failure by comparing ABO-incompatible and ABO-compatible transplantation outcomes. While the prior coverage of ACLF-specific prediction models focuses on mortality risk assessment, this meta-analysis provides evidence on the safety and efficacy of specific transplantation protocols for pediatric patients. The finding of comparable survival outcomes between ABO-i and ABO-c groups suggests that ABO-incompatibility does not negatively impact long-term survival in this population.

When a child needs a liver transplant, the biggest hurdle is often finding a donor with a matching blood type. For years, doctors have looked at whether using a donor with an incompatible blood type—meaning the blood types do not match—impacts the long-term survival of these young patients. This analysis looked at survival rates over one, three, and five years.

The findings show that children who received livers from incompatible donors had survival rates comparable to those who received compatible ones. The data also showed no significant differences in graft survival, vascular or biliary complications, or common infections like CMV and EBV. This suggests that the mismatch in blood type does not seem to compromise the primary goals of the surgery.

However, there is one important detail to note. Patients with mismatched blood types did show a significantly higher rate of antibody-mediated rejection, which is when the body's immune system attacks the new organ. Because this specific finding was based on only four studies, the overall certainty of the data is very low. These results are based on observational studies, which can have a risk of bias.

What this means for you:
Children with mismatched blood types have survival rates similar to those with matching blood types after liver transplants.

Common questions

Does a blood type mismatch affect a child's survival after a liver transplant?

No, the data shows that children who receive a liver from a donor with an incompatible blood type have survival rates at one, three, and five years that are comparable to those who receive a compatible liver.

Are there more complications for children with mismatched blood types?

The study found no significant differences in vascular or biliary complications, acute rejection, or common infections like CMV and EBV between the two groups. However, those with mismatched blood types did show a significantly higher rate of antibody-mediated rejection.

How certain are these results for pediatric patients?

The certainty of these findings is very low. The results are based on an observational design of included studies, which carries a risk of bias. You should discuss these specific risks and outcomes with a transplant specialist.

Study Details

Study typeMeta analysis
EvidenceLevel 1
Follow-up60.0 mo
PublishedSep 2026
View Original Abstract ↓
BACKGROUND AND OBJECTIVE: ABO-incompatible (ABO-i) liver transplantation (LT) in children is increasingly used to address organ scarcity, but concerns about immunological, vascular, and biliary complications remain. With evolving desensitization strategies and emerging pediatric data, an updated meta-analysis comparing ABO-i and ABO-compatible (ABO-c) LT is warranted. METHODS: PubMed, Embase, and Scopus were searched from inception to June 2026 to include studies evaluating ABO-i versus ABO-c LT in recipients ≤ 18 years of age. Primary outcomes were comparison of 1-, 3-, and 5-year patient and graft survival between the two groups. Secondary outcomes included comparisons of vascular and biliary complications, rejection, cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections, and post-transplant lymphoproliferative disease (PTLD). RESULTS: Seventeen studies were included. Patient survival was comparable between the two groups at 1 year (risk ratio [RR]: 0.97, 95% confidence interval [CI]: 0.94-1.0, p = 0.07), 3 years (RR: 0.98, 95% CI: 0.94-1.01, p = 0.22) and 5 years (RR: 0.97, 95% CI: 0.88-1.07, p = 0.50). Likewise, graft survival showed no significant differences. Incidence of vascular and biliary complications, acute rejection, CMV and EBV infection, and PTLD also did not differ significantly between groups. Antibody-mediated rejection (AMR) was significantly higher in ABO-i recipients (RR: 20.04, 95% CI: 3.25-123.56, p = 0.001), although this finding was based on only four studies. Overall, heterogeneity was low. Certainty of evidence was rated as very low, primarily due to the observational design of included studies and risk of bias. CONCLUSIONS: ABO-i LT in pediatric recipients demonstrates survival and complication outcomes comparable to those of ABO-c LT. However, very low certainty of evidence highlights the need for future well-designed prospective studies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.